Laura Shawver Sells 50,000 Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Stock
Director Laura Shawver sold 50,000 shares of the firm’s stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $11.10, for a total transaction of $555,000.00.
ARS Pharma seeks approval for epinephrine spray in Canada and UK
“With submission in Canada and the UK, ARS Pharma now has approval or has filed for approval in jurisdictions comprising more ...
ARS Pharmaceuticals Files for Approval of neffy® in Canada and the United Kingdom on Behalf of Licensing Partner ALK-Abelló A/S
Canada and United Kingdom represent two of the largest markets within the ALK portfolio with plans to expand filings of neffy ...
Pharmaceutical Technology9d
Sargramostim by Partner Therapeutics for Metastatic Melanoma: Likelihood of Approval
Sargramostim is under clinical development by Partner Therapeutics and currently in Phase III for Metastatic Melanoma.
pharmaphorum11d
FDA declines to approve needle-free epinephrine from ARS
In a statement, ARS Pharma said it was “very surprised” by the complete response letter (CRL) from the FDA as an advisory committee to the agency recommended approval of the drug in May ...
Yahoo Finance16d
Institutional owners may ignore ARS Pharmaceuticals, Inc.'s (NASDAQ:SPRY) recent US$67m market cap decline as longer-term profits stay in the green
To get a sense of who is truly in control of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY), it is important to understand the ownership structure of the business. We can see that institutions own the lion's ...
Morningstar20d
ARS Pharmaceuticals Announces neffy® (Epinephrine Nasal Spray) is available on Express Scripts Commercial National Formularies
This expanded access aligns with ARS Pharma’s commitment to reducing barriers to care and improving outcomes for patients who rely on epinephrine during allergy emergencies. ARS Pharma ...